Plamotamab (CD3E/MS4A1) Antibody, Monoclonal | 10-952

Plamotamab (CD3E/MS4A1) Antibody, Monoclonal | 10-952 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Chimeric, Humanized / CD3E/MS4A1 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa / scFv-h-CH2-CH3

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: XmAb-13676

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Plamotamab (XmAb13676) is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3) .An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on plamotamab.CD20 is highly expressed on B-cell tumor cells, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells.Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. The structural stability and modularity enabled by the XmAb Bispecific Fc domain allowed the tuning of plamotamab’s potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation.